Harrison.ai has been awarded three FDA breakthrough device designations for its imaging AI solutions, including a tool for obstructive hydrocephalus triage.
Key Details
- 1Harrison.ai received three FDA breakthrough device designations.
- 2One designation is for a triage/prioritization AI solution for obstructive hydrocephalus.
- 3The solution is among only 13% of FDA breakthrough devices to achieve 510(k) marketing authorization.
- 4It is one of only two radiology FDA breakthrough devices to become eligible for Medicare’s NTAP.
- 5The FDA program aims to speed up innovation and clinical access to critical devices.
Why It Matters
FDA breakthrough status highlights a product's potential to address unmet clinical needs, and rapid regulatory pathways can accelerate adoption in radiology practice. Harrison.ai's achievement signals growing validation and support for advanced imaging AI in critical care.
Source
Radiology Business
Related News
•Radiology Business
SimonMed Imaging Introduces Paid AI Add-Ons for Routine Exams
SimonMed Imaging is launching new AI-powered elective services for routine imaging exams with additional out-of-pocket costs for patients.
•Radiology Business
Aidoc Raises $150M to Expand Imaging AI Portfolio and Global Reach
Aidoc secures $150M in Series E funding led by Goldman Sachs to accelerate expansion of its clinical AI platform.
•Radiology Business
AI Model Outperforms Radiologists in Early Pancreatic Cancer Detection
REMOD, a new AI model, detects pancreatic cancer on CT scans much earlier and more accurately than radiologists.